IP Library Granted Patent US 7,902,187
Granted Patent B2
US 7,902,187 · App. 12/196,516 · Granted Mar 8, 2011

6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,902,187
App. No.
12/196,516
Granted
Mar 8, 2011
Kind
B2
Abstract

The present invention provides novel purinones and purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulae I and II shown below, in which Q is selected from the group consisting of CX and nitrogen; and A is chosen from the group consisting of H, (C 1 -C 6 ) alkyl, heteroaryl, and aryl:

Claims (26)

1. A compound of formula I or II

wherein

Q is selected from the group consisting of CX and nitrogen;

X is selected from the group consisting of hydrogen, halogen, and an electron-withdrawing group;

A is chosen from the group consisting of H, (C 1 -C 6 ) alkyl, heteroaryl, and aryl;

R 1 is selected from the group consisting of halogen, CN, (C 2 -C 6 ) alkyl, substituted (C 1 -C 6 ) alkyl, aryl, substituted aryl, azetidinyl, piperidinyl, piperazinyl, pyridinyl, pyrimidinyl, morpholinyl, thiomorpholinyl, pyrrolyl, pyrazolyl, indolyl, isoquinolinyl, azepinyl, diazepinyl, cyclobutyl, substituted azetidinyl, substituted piperidinyl, substituted piperazinyl, substituted pyridinyl, substituted pyrimidinyl, substituted morpholinyl, substituted thiomorpholinyl, substituted pyrrolyl, substituted pyrazolyl, substituted indolyl, substituted isoquinolinyl, substituted azepinyl, substituted diazepinyl, substituted cyclobutyl, and —V—R 7 ;

R 2 and R 3 are selected independently for each occurrence of (CR 2 R 3 ) from the group consisting of hydrogen and (C 1 -C 6 ) alkyl;

R 4 is selected from a group consisting of alkyl, OH, alkoxy, pyranyl, benzopyranyl, furanyl, pyridinyl, cyclohexyl, aryl, substituted alkyl, substituted pyranyl, substituted benzopyranyl, substituted furanyl, substituted pyridinyl, substituted cyclohexyl, and substituted aryl;

R 7 is chosen from H, (C 1 -C 6 ) alkyl, substituted (C 1 -C 6 ) alkyl, aryl, substituted aryl, pyridinyl, piperidinyl, furanyl, oxadiazolyl, azetidinyl, cyclopropyl, cyclobutyl, cyclopentyl, and substituted pyridinyl, substituted piperidinyl, substituted furanyl, substituted oxadiazolyl, substituted azetidinyl, substituted cyclopropyl, substituted cyclobutyl, substituted cyclopentyl;

V is chosen from —C(═O)O—, —C(═O)NR 8 —, —O—, and —NR 8 —;

R 8 is chosen from H and (C 1 -C 6 ) alkyl, or, azetidinyl, piperidinyl, oxadiazolyl, cyclopropyl, cyclobutyl, cyclopentyl, substituted azetidinyl, substituted piperidinyl, substituted oxadiazolyl, substituted cyclopropyl, substituted cyclobutyl, substituted cyclopentyl;

R 9 is chosen from hydrogen, alkyl, and substituted alkyl; and

y is zero or an integer selected from 1, 2, 3, and 4.

2. A compound according to claim 1 , wherein R 9 is hydrogen and R 1 is chosen from aryl, substituted aryl, azetidinyl, piperidinyl, piperazinyl, pyridinyl, pyrimidinyl, morpholinyl, thiomorpholinyl, pyrrolyl, pyrazolyl, indolyl, isoquinolinyl, azepinyl, diazepinyl, cyclobutyl, and substituted azetidinyl, substituted piperidinyl, substituted piperazinyl, substituted pyridinyl, substituted pyrimidinyl, substituted morpholinyl, substituted thiomorpholinyl, substituted pyrrolyl, substituted pyrazolyl, substituted indolyl, substituted isoquinolinyl, substituted azepinyl, substituted diazepinyl, substituted cyclobutyl.

3. A compound according to claim 2 , wherein R 1 is chosen from pyridinyl, pyrazolyl, pyrimidinyl, isoquinolinyl, azetidinyl, piperidinyl, piperizinyl, pyrrolidinyl, morpholinyl, azepanyl, diazepanyl, and phenyl optionally substituted with hydroxy, halogen, carboxamido, alkyl, carboxy, sulfonyl, alkoxy, and cyano.

4. A compound according to claim 1 , wherein R 1 is chosen from aryl, substituted aryl, (C 1 -C 6 ) alkyl, and substituted (C 1 -C 6 ) alkyl.

5. A compound according to claim 1 , wherein R 1 is V—R 7 .

6. A compound according to claim 5 , wherein V is —C(═O)O— or —C(═O)NR 8 —, and R 7 is chosen from —CH 2 CN 3 (C 1 -C 6 ) alkyl, and H, or VR 7 is

7. A compound according to claim 5 , wherein V is chosen from —O— and —NR 8 —; R 7 is (C 1 -C 6 ) alkyl; and R 8 is H.

8. A compound according to claim 1 , wherein R 9 is hydrogen, y is zero and R 4 is a residue selected from a monocycle, a bicycle, a substituted monocycle, and a substituted bicycle, said residue containing at least one oxygen atom.

9. A compound according to claim 8 , wherein R 4 is chosen from pyranyl, benzopyranyl, furanyl, substituted pyranyl, substituted benzopyranyl, substituted furanyl, a hydroxyl-substituted cycloalkyl, an alkoxy-substituted aryl, and a hydroxyl-substituted aryl.

10. A compound according to claim 9 , wherein R 4 is chosen from

wherein R 6 is hydrogen or fluorine, and the carbon marked with an asterisk is of the R absolute configuration.

11. A compound according to claim 1 , wherein R 9 is hydrogen, y is 1-4, R 2 and R 3 are hydrogen in all occurrences, and R 4 is alkoxy or OH of formula Ib or IIb:

wherein R 5 is hydrogen or (C 1 -C 6 ) alkyl.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1 .

Assignments (6)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 27, 2023
From: WYETH LLC
To: WYETH LLC
Reel/Frame 063165/0455 →
CORRECTIVE ASSIGNMENT TO CORRECT THE WORDING OF ASSIGNOR NAME PHARMACOPEIA INC. PREVIOUSLY RECORDED ON REEL 024998 FRAME 0836. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT WORDING AS PHARMACOPEIA LLC Recorded Feb 9, 2011
From: PHARMACOPEIA LLC
To: WYETH LLC
Reel/Frame 025778/0127 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT APPLICATION NUMBER: 12/195,616 PREVIOUSLY RECORDED ON REEL 025539 FRAME 0463. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT APPLICATION NUMBER: 12/196,516. Recorded Jan 31, 2011
From: PHARMACOPEIA, INC
To: PHARMACOPEIA, LLC
Reel/Frame 025722/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2010
From: PHARMACOPEIA, INC.
To: WYETH LLC
Reel/Frame 024998/0836 →
MERGER Recorded Jul 28, 2009
From: PHARMACOPEIA, INC.; LATOUR ACQUISITION, LLC
To: PHARMACOPEIA, LLC
Reel/Frame 023018/0384 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2008
From: NEAGU, IRINA; DILLER, DAVID; KINGSBURY, CELIA; BOHNSTEDT, ADOLPH C.; OHLMEYER, MICHAEL J.; PARADKAR, VIDYADHAR; ANSARI, NASRIN
To: PHARMACOPEIA, INC.
Reel/Frame 021896/0602 →